Earnings Call · Q3 FY2025·2025-11-06

Q3 25EPS +7.55%·Rev n/aQ2 25EPS +16.92%·Rev n/aQ1 25EPS -3.77%·Rev n/aQ4 24EPS +27.63%·Rev n/a⚠ consensus missing

LISATA THERAPEUTICS, INC. LSTA

John Menditto — Vice President of Investor Relations

David Mazzo — President and Chief Executive Officer

James Nisco — Financial Officer or similar (presenting financial results)

Kristen Buck — Executive (Clinical Development) or similar

−12.3%1d on move date−12.4% vs SPY3d−10.6%5d−11.9%

Research tier

Behavioral profile computed for 4 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more LSTA calls or request research access.

More LSTA calls Browse calls Request research access